Cancer Biotherapy and Radiopharmaceuticals (ISSN 1084-9785, 1557-8852) is a journal published by Mary Ann Liebert Inc. in the United States. It covers Biochemistry, Genetics and Molecular Biology, Medicine and Pharmacology. It is indexed in Scopus, Web of Science, MEDLINE, PubMed and HEC. Recorded metrics: impact factor 1.7, Scopus Q2, Web of Science Q3, CiteScore 5.9 and HEC W-Category. Article processing charge: USD 4,440.
Cancer Biotherapy and Radiopharmaceuticals
Record last updated . Check current status at HEC HJRS, Scopus and the Web of Science Master Journal List before submitting. About our data.
Journal lists: Q2 journals · Q3 journals · HEC W category journals · Scopus journals · Web of Science journals · MEDLINE journals · PubMed journals · SCImago journals · SCIE journals
Quick answers about Cancer Biotherapy and Radiopharmaceuticals
Is Cancer Biotherapy and Radiopharmaceuticals HEC recognised?
Yes. The catalogue records Cancer Biotherapy and Radiopharmaceuticals in HEC category W of the HEC Journal Recognition System, where W is the highest and Y the lowest category. Confirm the current category on HEC's HJRS website before you submit.
Is Cancer Biotherapy and Radiopharmaceuticals indexed in Scopus?
Yes. Cancer Biotherapy and Radiopharmaceuticals is listed as Scopus-indexed, in quartile Q2, with a CiteScore of 5.9. Check its current status on the Scopus Sources page.
Is Cancer Biotherapy and Radiopharmaceuticals in Web of Science?
Yes. Cancer Biotherapy and Radiopharmaceuticals is listed as a Web of Science journal in the Science Citation Index Expanded (SCIE), with Web of Science quartile Q3. Confirm on Clarivate's Master Journal List.
What is the impact factor of Cancer Biotherapy and Radiopharmaceuticals?
The recorded journal impact factor of Cancer Biotherapy and Radiopharmaceuticals is 1.7. Clarivate updates impact factors every year in Journal Citation Reports.
Is Cancer Biotherapy and Radiopharmaceuticals open access, and what does it charge?
Cancer Biotherapy and Radiopharmaceuticals is not recorded as fully open access and its APC is USD 4,440. Fees change, so check the journal's website before you submit.
Who publishes Cancer Biotherapy and Radiopharmaceuticals?
Cancer Biotherapy and Radiopharmaceuticals is published by Mary Ann Liebert Inc. in United States, under ISSN 1084-9785 and 1557-8852.
Research profile
- 2,500articles indexed
- 49,979citations
- 83h-index
- 1.852-year mean citedness
- 1996first year indexed
Main research topics: Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications, Cancer-related molecular mechanisms research, MicroRNA in disease regulation, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research.
Source: OpenAlex (CC0), retrieved 20 November 2026. Counts cover works OpenAlex has indexed and differ from Scopus and Web of Science.
Browse similar journals
- Biochemistry journals (2,271)
- Genetics and Molecular Biology journals (2,271)
- Medicine journals (8,012)
- Journals indexed in Scopus (32,207)
- Journals indexed in Web of Science (22,643)
- Journals indexed in MEDLINE (3,645)
- Journals indexed in PubMed (16,086)
- Journals indexed in HEC (34,823)
- Scopus Q2 journals (7,916)
- Web of Science Q3 journals (8,657)
- HEC W-Category journals (13,616)
- Journals published in the United States (7,562)
- Mary Ann Liebert Inc. journals (92)